Grifols, S.A.

NasdaqGS:GRFS Stok Raporu

Piyasa değeri: US$6.8b

Grifols Yönetim

Yönetim kriter kontrolleri 3/4

Grifols CEO'su Nacho Abia Buenache, Apr2024 tarihinde atandı, in görev süresi 2.08 yıldır. in toplam yıllık tazminatı € 3.52M olup, şirket hissesi ve opsiyonları dahil olmak üzere 56.9% maaş ve 43.1% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.019% ine doğrudan sahiptir ve bu hisseler $ 1.28M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 7.3 yıl ve 7 yıldır.

Anahtar bilgiler

Nacho Abia Buenache

İcra Kurulu Başkanı

€3.5m

Toplam tazminat

CEO maaş yüzdesi56.87%
CEO görev süresi2.1yrs
CEO sahipliği0.02%
Yönetim ortalama görev süresi7.3yrs
Yönetim Kurulu ortalama görev süresi7yrs

Son yönetim güncellemeleri

Recent updates

Seeking Alpha • Dec 08

Grifols: Positive/Neutral Scenario Posits An Upside

Summary Grifols, S.A. has executed a turnaround, with Q3 '25 results confirming improved fundamentals, reduced leverage, and restored dividend, supporting a renewed 'Buy' rating. GRFS now trades at a normalized P/E of 14-15x, but forward multiples drop below 9x, offering significant upside if growth forecasts materialize. Operational improvements include 7%+ revenue growth, double-digit EBITDA gains, positive FCF, and leverage below 4.3x, with further refinancing underway. My GRFS share price target reflects double-digit annualized upside potential, underpinned by forecasted EPS growth and multiple expansion, despite lingering competitive and leverage risks. Read the full article on Seeking Alpha
Seeking Alpha • Apr 23

Grifols: A Market Setback Turns Into Buying Opportunity

Summary Grifols, a Spanish multinational specializing in plasma-derived therapies, is undervalued due to historical mismanagement but holds a strong market position with significant competitive advantages. New management has implemented an operational improvement plan, showing positive results in 2024, including record revenues, improved EBITDA margins, and increased free cash flow. Key risks include potential U.S. immigration policies affecting plasma supply and the emergence of recombinant protein substitutes, which could erode revenue by 2028. The business is poised for growth with a strategic plan targeting revenue growth, improved margins, and significant free cash flow generation, making it an attractive investment opportunity. Read the full article on Seeking Alpha
Seeking Alpha • Feb 27

Grifols: Looking At The Longer-Term 2025-2027 Upside After No Sale

Summary Grifols remains a strong long-term investment due to its leading position in the plasma industry and improving financial fundamentals, despite short-term volatility and lack of a dividend. The company's revenue and EBITDA growth, improved leverage ratio, and significant liquidity highlight its resilience and potential for future profitability. Grifols' valuation is attractive, with a potential upside to €20/share, driven by EPS growth and market expansion in plasma-derived products. I maintain a "BUY" rating for Grifols, expecting a significant return on investment over the next 1-4 years. Read the full article on Seeking Alpha
Seeking Alpha • Nov 29

Grifols: More Attractive Than In A Very Long Time

Summary I don't divest unless the fundamental thesis changes; Grifols' buyout offer from Brookfield Asset Management is undervalued, so I maintain my "Buy" stance. Despite Brookfield's offer, I believe Grifols is worth more, as supported by recent 3Q24 results and the transaction committee's recommendation. The transaction committee advises against accepting the €10.5/share offer, aligning with my view that Grifols' real value is higher. This situation is instructive for valuation investors, demonstrating the importance of assessing a company's true worth beyond buyout offers. Read the full article on Seeking Alpha
Seeking Alpha • Oct 03

Grifols: Here Is Why It's Still A 'Buy' Even If Price Goes Down

Summary Grifols, S.A. is undervalued and worth more than its current market valuation, making it a strong buy even without a potential Brookfield buyout. The company leads the global plasma market, with significant growth in immunoglobulin and albumin segments, and has a robust infrastructure and geographical reach. Despite facing competition and emerging technologies, Grifols' fundamentals are solid, with impressive 2024 earnings forecasts and improving margins and leverage. The lack of a dividend is a downside, but the potential for significant returns based on historical P/E ratios makes Grifols a speculative “Buy”. Read the full article on Seeking Alpha
Seeking Alpha • Jul 16

Grifols: Stay On The Sidelines

Summary Grifols leverage and governance concerns are primarily addressed. The company confirms discussions around a potential combined PE/family bid offer. Still, there is a high debt and negligible FCF generation to consider. We remain neutral. Read the full article on Seeking Alpha
Seeking Alpha • May 07

Grifols: Why To Watch From The Sidelines

Summary Grifols, a major player in global plasma extraction and processing, has experienced a significant 43% decline in stock price in 2024 following a bearish report from Gotham. KPMG and the Spanish regulator have offered a more favorable perspective based on Grifols’ 2023 results, suggesting that while the company’s structure warrants caution, it is not without value. For investors seeking value, the question is: Is there enough margin of safety? A closer examination reveals that Grifols is facing several challenges compared to its competitors, compounded by debt. Read the full article on Seeking Alpha
Seeking Alpha • Mar 05

Grifols: Q4 Was Positive, Still Too Many Question Marks

Summary Grifols faces new accusations from the hedge fund Gotham City. Gotham City questions loans and outgoing flows recorded in Grifols' financial report, as well as the role of Scranton Enterprises. Grifols disclosed a lack of FCF generation in 2024. We are neutral, given a soft outlook for the current year. On a positive note, Grifols confirmed the Shanghai RAAS equity stake divestment. Read the full article on Seeking Alpha
Seeking Alpha • Jan 10

Grifols: I've Read The Short-Seller Report, And I Mostly Disagree

Summary Grifols' position in the pharma industry has dropped due to a short-seller report, causing its stock to decline. The report questions the accounting treatment of M&As and consolidation of entities in Grifols' filings. I believe that the allegations in the report are not significant enough to warrant a 20% drop in the company's stock and plans to wait for a reaction before adding more to their stake. Read the full article on Seeking Alpha

CEO Tazminat Analizi

Nacho Abia Buenache'un ücretlendirmesi Grifols'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Mar 31 2026n/an/a

€415m

Dec 31 2025€4m€2m

€402m

Tazminat ve Piyasa: Nacho 'nin toplam tazminatı ($USD 4.09M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 8.38M ).

Tazminat ve Kazançlar: Nacho şirketinin tazminatını şirket performansıyla karşılaştırmak için yeterli veri yok.

CEO

Nacho Abia Buenache (57 yo)

2.1yrs
Görev süresi
€3,517,000
Tazminat

Mr. Jose Ignacio Abia Buenache, also known as Nacho, serves as Chief Executive Officer of Grifols, S.A. from April 1, 2024 and has been its Director since February 26, 2024. Mr. Abia Buenache had been Chie...

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Jose Ignacio Abia Buenache
CEO & Director2.1yrs€3.52m0.019%
$ 1.3m
Rahul Srinivasan
Chief Financial Officer1.7yrsVeri yok0.0015%
$ 102.7k
Lluis Gomez
Senior Vice President of Strategy & COO Officeno dataVeri yokVeri yok
Daniel Segarra
Head of Investor Relations & Sustainability and Vice Presidentno dataVeri yokVeri yok
David Bell
Chief Corporate Affairs & Legal Officer23.3yrsVeri yok0.0029%
$ 200.0k
Enrique de la Torre
Chief Compliance Officer7.3yrsVeri yokVeri yok
Montse Ribas
Chief Communications and Reputation Officer1.2yrsVeri yokVeri yok
Camille Alpi
Chief Human Resources & Talent Officer2.3yrsVeri yokVeri yok
Vicente Blanquer Torre
Chief Quality Officer33.3yrsVeri yokVeri yok
Sergio Adell
President of Commercial Tech Support7.3yrsVeri yokVeri yok
Daniel Coit
Chief Industrial Services Officer7.3yrsVeri yokVeri yok
Luis Garçon
Managing Director Laboratorios Grifols7.8yrsVeri yokVeri yok
7.3yrs
Ortalama Görev Süresi
53yo
Ortalama Yaş

Deneyimli Yönetim: GRFS 'un yönetim ekibi deneyimli ve deneyimlidir ( 7.3 yıldır).

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Jose Ignacio Abia Buenache
CEO & Director2.3yrs€3.52m0.019%
$ 1.3m
Iñigo Mardones
Independent Director11yrs€164.00kVeri yok
Victor Grifols Roura
Chairman of Honourno data€129.00kVeri yok
Juan Twose Roura
Member of the Advisory Committee11.3yrs€380.00kVeri yok
Raimon Grifols Roura
Vice-Chairman11yrs€129.00k0.033%
$ 2.2m
Tomas Daga Gelabert
Independent External Director26.1yrs€129.00k0.044%
$ 3.0m
Víctor Grifols Deu
Proprietary Director10yrs€4.45m0.016%
$ 1.1m
Albert Coma-Cros
Proprietary Director2.4yrs€129.00kVeri yok
Enriqueta Font
Independent Director7yrs€139.00kVeri yok
Montserrat Abellana
Independent Director3.9yrs€164.00kVeri yok
Susana Gonzalez Rodriguez
Independent Director3.9yrs€154.00kVeri yok
Anne-Catherine Berner
Independent Chairman1.9yrs€380.00kVeri yok
7.0yrs
Ortalama Görev Süresi
61yo
Ortalama Yaş

Deneyimli Yönetim Kurulu: GRFS 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 7 yıldır).

Şirket Analizi ve Finansal Veri Durumu

VeriSon Güncelleme (UTC saati)
Şirket Analizi2026/05/26 00:30
Gün Sonu Hisse Fiyatı2026/05/26 00:00
Kazançlar2026/03/31
Yıllık Kazançlar2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

PaketVeriZaman ÇerçevesiÖrnek ABD Kaynağı *
Şirket Finansalları10 yıl
  • Gelir tablosu
  • Nakit akış tablosu
  • Bilanço
Analist Konsensüs Tahminleri+3 yıl
  • Finansal tahminler
  • Analist fiyat hedefleri
Piyasa Fiyatları30 yıl
  • Hisse senedi fiyatları
  • Temettüler, Bölünmeler ve Eylemler
Sahiplik10 yıl
  • En büyük hissedarlar
  • İçeriden öğrenenlerin ticareti
Yönetim10 yıl
  • Liderlik ekibi
  • Yönetim Kurulu
Önemli Gelişmeler10 yıl
  • Şirket duyuruları

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Grifols, S.A. 32 Bu analistlerden 11, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

AnalistKurum
null nullBanco de Sabadell. S.A.
Luis ArredondoBanco de Sabadell. S.A.
Jaime EscribanoBanco Santander